More recently, a phase 2, multicenter, double-blind, randomized, placebo-controlled study started recruiting a minimum of sixty patients diagnosed with PD and carriers of GBA mutations, who will be recruited and randomly allocated to either oral Ambroxol 1.2 g/day or placebo (ClinicalTrials.gov ID: NCT05287503). This evidence concerns the gene GBA1 and Parkinson disease.